Related Experiment Video
Updated: May 3, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
14.2K
Focal adhesion protein expression in human diffuse large B-cell lymphoma.
Rosa Bosch1, Rebeca Dieguez-Gonzalez, María José Moreno
1Grup d'Oncogènesi i Antitumorals, Institut d'Investigacions Biomèdiques Sant Pau, Barcelona, Spain.
Histopathology
|January 29, 2014
Summary
Decreased focal adhesion kinase (FAK) expression predicts a poorer prognosis in diffuse large B-cell lymphoma (DLBCL). FAK immunostaining may improve risk stratification for DLBCL patients.
Area of Science:
- Oncology
- Cell Biology
- Hematology
Background:
- Focal adhesions are linked to poor prognosis in various cancers.
- The prognostic significance of focal adhesions in diffuse large B-cell lymphoma (DLBCL) remains uninvestigated.
Purpose of the Study:
- To examine the expression patterns of focal adhesion proteins FAK, Pyk2, p130Cas, and HEF1 in DLBCL.
- To determine the prognostic value of these proteins in DLBCL.
Main Methods:
- Immunohistochemistry was used to analyze focal adhesion protein expression in normal lymphoid tissues and 60 DLBCL samples.
- Kaplan-Meier survival and Cox regression analyses were employed to assess prognostic correlations.
Main Results:
- FAK, Pyk2, p130Cas, and HEF1 were primarily detected in germinal centers of normal lymphoid tissues.
- High expression of FAK, Pyk2, p130Cas, and HEF1 was observed in 45%, 34%, 42%, and 45% of DLBCL samples, respectively.
- Reduced FAK expression emerged as an independent predictor of unfavorable disease outcomes in multivariate Cox analysis.
Conclusions:
- Focal adhesion kinase (FAK) expression serves as an independent prognostic factor in DLBCL.
- Incorporating FAK immunostaining into current immunohistochemical algorithms could enhance risk stratification for DLBCL patients.
